Clover Health exits ACO REACH
The beleaguered insurer will leave the accountable care program at the end of the 2023 performance year following disappointing results in Medicare direct contracting.
The beleaguered insurer will leave the accountable care program at the end of the 2023 performance year following disappointing results in Medicare direct contracting.
The Baird survey of 38 health system CFOs forecasts that hospital capital spending growth in 2024 will slow from a 13% jump this year.
US hospitals forecast 9% capex growth to support elective procedure backlog: survey Read More »
The company and claimants in Georgia filed to dismiss cases related to Ethicon’s Physiomesh in late November.
J&J hernia mesh settlement prompts judge to dismiss more than 200 cases Read More »
The company outlined its long-term growth expectations and confirmed that it has no plans to separate its medtech and pharma segments.
As the rate of corporate-owned healthcare practices rise, providers say a lack of autonomy leads to diminished patient care.
Corporate healthcare ownership reduces care quality, physician survey finds Read More »
The name change comes nearly two years after the merger between the health systems closed.
Chicago-area NorthShore – Edward-Elmhurst rebrands to Endeavor Health Read More »
The for-profit operator said low reimbursement rates and financial challenges will cause it to shutter the 182-bed facility.
Steward Health Care to close Massachusetts hospital amid financial troubles Read More »
El dolor cervical es una condición que afecta a millones de personas en todo el mundo, manifestándose como molestias, rigidez y tensión en la zona del cuello. Este problema puede derivar de diversas causas, desde malas posturas hasta lesiones, estrés crónico o enfe …
¿Cómo dormir con dolor cervical? Consejos y trucos para un sueño reparador Read More »
VitriVax, Inc ., a formulation technology company, announced today a $5M two-year grant from the Bill & Melinda Gates Foundation.
VitriVax Receives $5M Grant for Vaccine Development Read More »
Syros Pharmaceuticals today announced strong and encouraging initial data from its ongoing SELECT-AML-1 Phase 2 trial evaluating tamibarotene, an oral, selective, retinoic acid receptor alpha (RARα) agonist.